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Abstract Treatment options for chronic hepatitis C virus
(HCV) infection have drastically changed since the
development and licensing of new potent direct-acting
antivirals (DAAs). The majority of DAAs are extensively
metabolized by liver enzymes and have the ability to
influence cytochrome P450 (CYP) enzymes. Additionally,
these DAAs are both substrates and inhibitors of drug
transporters, which makes the DAAs both possible victims
or perpetrators of drug–drug interactions (DDIs). There is a
high prevalence of mental illnesses such as depression or
psychosis in HCV-infected patients; therefore, psychoac-
tive medications are frequently co-administered with
DAAs. The majority of these psychoactive medications are
also metabolized by CYP enzymes but remarkably little
information is available on DDIs between psychoactive
medications and DAAs. Hence, the aim of this review is to
provide an overview of the interaction mechanisms
between DAAs and psychoactive agents. In addition, we
describe evidenced-based interactions between DAAs and
psychoactive drugs and identify safe options for the
simultaneous treatment of mental illnesses and chronic
HCV infection.
Key Points
Escitalopram and citalopram have been studied in
combination with most direct-acting antivirals
(DAAs) and either of these drugs can be safely
combined with hepatitis C virus (HCV) treatment.
No formal interaction studies between psychoactive
agents and sofosbuvir or ledipasvir have been
performed in humans. However, these DAAs are
generally neither victims nor perpetrators of drug
interactions and can therefore be safely used in
combination with psychoactive drugs.
Boceprevir, simeprevir, and the combination
paritaprevir/ritonavir plus ombitasvir with dasabuvir
are most likely to cause drug interactions via the
inhibition of cytochrome P450 (CYP) 3A4.
Therefore, caution must be exercised when CYP3A4
substrates such as midazolam and/or quetiapine are
co-administered with these DAAs.
1 Introduction
One of the components previously used in the treatment
regimen for hepatitis C virus (HCV) is pegylated inter-
feron; however, it has major adverse effects on mental
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health and depression was a commonly seen adverse event
[1]. Since the development of novel direct-acting antivirals
(DAAs), pegylated interferon is no longer used in the
treatment of HCV infections in resource-rich settings.
However, the prevalence of mental disorders remains high
among untreated HCV-infected patients [2]. For example, a
retrospective study reported that 86 % of HCV-infected
patients had at least one psychiatric, drug-, or alcohol use-
related disorder recorded in their patient charts. The most
common conditions were depressive disorders (50 %),
psychosis (50 %), anxiety disorders (41 %), post-traumatic
stress disorders (34 %), and bipolar disorders (16 %) [3].
Another study reported a prevalence of 41 % for anxiety
and 27 % for depression in HCV-infected individuals
(n = 395) [4]. One explanation for this high prevalence
was that patients with mental disorders are more likely to
have a drug addiction, because intravenous drug use is a
major route of HCV transmission [5].
The results from a cross-sectional study were in agree-
ment with the high prevalence of mental disorders. In that
study, 16 % of the HCV-infected patients were on antide-
pressants and 10 % were on antipsychotics (n = 3716) [6].
This corresponds with data from a Dutch nationwide sur-
vey in which benzodiazepines, drugs used for treating
opioid dependence, and selective serotonin reuptake inhi-
bitors (SSRIs) were among the drugs most frequently used
by chronic HCV-infected patients [7].
The use of antipsychotics and antidepressants during
DAA therapy increases the risk of drug-drug interactions
(DDIs). Both DAAs and psychoactive agents are exten-
sively metabolized in the liver and have the ability to affect
the activities of various enzymes (e.g., cytochrome P450
[CYP]) and drug transporters (e.g., P-glycoprotein [P-gp]).
This makes DAAs as well as psychoactive agents possible
victims (objects of DDIs) and perpetrators (causes of DDIs)
of drug interactions, which could negatively affect treat-
ment outcomes as a result of adverse effects (increased
plasma concentrations) or treatment failure (decreased
plasma concentrations) [8, 9]. In order to interpret the DDIs
between DAAs and psychoactive agents, it is important to
have sufficient knowledge of their therapeutic ranges.
Benzodiazepines, tricyclic antidepressants (TCAs), and
antipsychotics have a narrow therapeutic range, while
SSRIs have a broad therapeutic range. Generally, drugs
with narrow therapeutic ranges are more likely to have
clinically relevant DDIs than drugs with large therapeutic
ranges [10]. DAAs have a large therapeutic range, which
makes them less susceptible to the effects of an increase or
decrease in their plasma concentrations caused by, for
example, CYP inhibition or induction. However, extremely
low plasma concentrations could lead to virologic failure.
Little information is available on interactions between
DAAs and psychoactive agents. Therefore, the aim of this
review is to provide an overview of the interaction mech-
anisms of DAAs and psychoactive agents. In addition, we
describe evidenced-based interactions between DAAs and
psychoactive drugs and identify safe options for treatment
of the simultaneous treatment of mental illnesses and HCV
infection.
2 Methods
We searched PubMed (1946–January 2016) and EMBASE
(1947–January 2016) to identify peer-reviewed studies.
The search covered all DAAs recommended in European
and US guidelines [11, 12] and licensed by the European
Medicines Agency (EMA) and US Food and Drug
Administration (FDA). The DAAs included protease inhi-
bitors (PIs) (boceprevir, simeprevir, paritaprevir, and gra-
zoprevir), NS5A inhibitors (daclatasvir, ledipasvir,
ombitasvir, and elbasvir), and NS5B polymerase inhibitors
(sofosbuvir and dasabuvir). Telaprevir (PI) was excluded
from the review because it has limited use in current
therapy. We also referred to the work published by Kiser
and colleagues [13] for more information about telaprevir
and DDIs between DAAs and psychoactive drugs.
The psychoactive agents included were SSRIs, TCAs,
typical and atypical antipsychotics, benzodiazepines,
monoamine oxidase inhibitors, lithium, and St John’s wort.
The Google and Google Scholar search engines, and
ClinicalTrials.gov (http://www.clinicaltrials.gov) website
and the Liverpool drug interaction database (http://www.
hep-druginteractions.org) were used to identify conference
papers and abstracts. All searches were performed in
English. The search items contained generic and/or brand
names of the drugs and included terms such as antide-
pressant, antipsychotic, sedative, and tranquilizer.
Information about the pharmacokinetics and metabolism
of the DAAs and psychoactive agents were obtained from
the Summary of Product Characteristics (SmPC) and FDA
prescribing information for each drug as well as from the
Lexicomp database (available via http://www.uptodate.
com). Enzyme inhibitors and inducers were defined as
being strong, moderate, or weak if they changed the area
under the plasma concentration–time curve (AUC) of a
substrate by 5-fold,[2 to\5-fold, and\2-fold, respec-
tively. Substrates were also grouped as being minor and
major substrates of enzymes. These groupings were based
on the clinical relevance of the potential interaction
described by Lexicomp (http://www.uptodate.com)
[14, 15].
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3 Drug-Drug Interaction (DDI) Mechanisms:
Direct-Acting Antivirals (DAAs)
In this section, we elaborate on the mechanisms by which
DAAs can be perpetrators and/or victims of DDIs. We
focused on interactions through hepatic drug metabolism
and drug transporters because they are the most important
pathways underlying interactions between DAAs and
psychoactive agents. These mechanisms are illustrated
using examples of drug interactions between DAAs and
psychoactive agents or non-psychoactive drugs, which
were studied in healthy volunteers.
Tables 1 and 2 give an overview of the involvement of
enzymes and drug transporters in the metabolism of DAAs
and psychoactive agents, respectively. Table 3 shows the
results of drug interaction studies performed between
DAAs and psychoactive drugs.
3.1 Phase I and II Reactions: DAAs as Perpetrators
Drugs that influence drug-metabolizing enzymes (perpe-
trators) such as CYP and uridine diphosphate glucuronyl-
transferase (UGT) have the ability to affect the plasma
concentration of substrates of the enzymes (victims).
Inhibitors of CYP and UGT generally cause an increased
plasma concentration of the victim, while inducers usually
lower the plasma concentration of the victim.
Ritonavir is included in the fixed-dose combination
with paritaprevir, ombitasvir, and dasabuvir to ‘boost’ the
pharmacokinetic characteristics of paritaprevir through the
inhibition of CYP3A4; this opens the door for DDIs to
occur. For example, the AUC and maximum plasma
concentration (Cmax) of orally administered midazolam, a
CYP3A4 substrate, increased *26-fold and *4-fold,
respectively, when midazolam was co-administered with
ritonavir (note: the interaction between ritonavir and
midazolam is studied in the absence of paritaprevir,
ombitasvir, or dasabuvir) [16]. Increases in the plasma
concentration of midazolam have also been observed
when the drug was administered with boceprevir,
simeprevir, and grazoprevir, which are also CYP3A4
inhibitors. Boceprevir is a strong inhibitor of CYP3A4,
while simeprevir and grazoprevir are mild CYP3A4
inhibitors (Table 3) [17–19].
UGTs are inhibited by DAAs such as ombitasvir,
dasabuvir, and paritaprevir. Lorazepam (benzodiazepine) is
a UGT substrate; however, this interaction has not been
studied. Interaction studies between furosemide (UGT1A1
substrate) and combination regimen paritaprevir/ritonavir,
ombitasvir, and dasabuvir have indicated the importance of
UGT inhibition. Results from these studies showed that the
AUC and Cmax of furosemide were increased by 8 and
42 %, respectively. As a result of this, a reduction in the
dose of furosemide of up to 50 % might be required if the
drugs have to be co-administered [20].
3.2 Phase I and II Reactions: DAAs as Victims
DAAs, e.g., daclatasvir, simeprevir, grazoprevir, and
elbasvir, are predominantly metabolized by CYP3A4/5 in
the liver and gastrointestinal tract. Thus, caution is needed
when DAAs are administered with strong inducers or
inhibitors of CYP3A4. A reduced plasma concentration of
DAAs creates a potential risk of resistance of the virus to
the administered drug and/or virologic failure, while ele-
vated drug concentrations increase the risk of adverse
events. Most psychoactive agents do not strongly inhibit or
induce CYP3A4 and, thus, we do not expect DAAs to be
victims of psychoactive agents. St John’s wort, which is a
psychoactive agent, is the exception; it is a strong CYP3A4
inducer. However, co-administration of boceprevir and St
John’s wort showed only a slight decrease in the plasma
concentration of boceprevir (9 %) [21].
DAAs are not metabolized by UGT or other phase II
enzymes; therefore, phase II-mediated DDIs with DAAs as
victims are not usually expected.
3.3 Drug Transporters: DAAs as Perpetrators
DAAs inhibit various drug transporters such as the efflux
transporters P-gp and breast cancer resistance protein
(BCRP) (Table 1), which are, among other located at the
blood–brain barrier (BBB). Little information is available
on DDIs between psychoactive agents and drug trans-
porters. However, it is known that amitriptyline and
risperidone are P-gp substrates (Table 2). Accordingly,
inhibition of these transporters increases substrate con-
centrations in the cerebrospinal fluid [22]. Since the phar-
macological action of psychoactive drugs takes place in the
brain, inhibition of P-gp can result in an increased phar-
macological effect.
No formal interaction studies have been conducted
between the P-gp substrates and DAAs. The effect of P-gp
inhibition by DAAs has been studied using digoxin, which
is a known P-gp substrate. Boceprevir had a minor influ-
ence on plasma digoxin concentrations (an increase in
AUC and Cmax by 19 and 18 %, respectively) [17].
Daclatasvir and simeprevir also affected digoxin plasma
concentrations; the AUC of digoxin was increased by 27
and 39 %, and Cmax was increased by 65 and 31 %,
respectively [18, 23]. It should be noted that these inter-
actions between the P-gp inhibitors and digoxin were dri-
ven by the concentration of digoxin in the intestinal lumen,
which is high after oral intake. For psychoactive drugs,
DDIs Between DAAs and Psychoactive Medications 1473
T
a
b
le
1
O
v
er
v
ie
w
o
f
th
e
ro
u
te
o
f
m
et
ab
o
li
sm
,
ef
fe
ct
s
o
n
en
zy
m
es
,
an
d
tr
an
sp
o
rt
er
s
o
f
d
ir
ec
t-
ac
ti
n
g
an
ti
v
ir
al
s
D
ru
g
E
n
zy
m
e
T
ra
n
sp
o
rt
er
C
o
m
m
en
ts
R
ef
er
en
ce
s
S
u
b
st
ra
te
In
h
ib
it
o
r
S
u
b
st
ra
te
In
h
ib
it
o
r
P
ro
te
as
e
in
h
ib
it
o
rs
B
o
ce
p
re
v
ir
A
K
R
-m
ed
ia
te
d
p
at
h
w
ay
C
Y
P
3
A
4
/5
C
Y
P
3
A
4
/5
P
-g
p
(m
il
d
)
[1
7
]
S
im
ep
re
v
ir
C
Y
P
3
A
4
In
te
st
in
al
C
Y
P
3
A
4
C
Y
P
1
A
2
(w
ea
k
)
O
A
T
P
1
B
1
/3
P
-g
p
[1
8
]
P
ar
it
ap
re
v
ir
C
Y
P
3
A
4
/5
U
G
T
1
A
1
P
-g
p
O
A
T
P
1
B
1
B
C
R
P
O
A
T
P
1
B
1
/3
O
A
T
P
2
B
1
B
R
C
P
[2
0
]
R
it
o
n
av
ir
C
Y
P
3
A
4
C
Y
P
2
D
6
(l
es
se
r
ex
te
n
t)
C
Y
P
3
A
4
C
Y
P
2
D
6
(?
)
In
d
u
ce
r
C
Y
P
2
C
1
9
In
d
u
ce
r
C
Y
P
1
A
O
A
T
P
2
B
1
O
C
T
1
(?
)
B
R
C
P
[2
0
]
G
ra
zo
p
re
v
ir
C
Y
P
3
A
4
C
Y
P
3
A
4
(m
il
d
)
O
A
T
P
1
B
1
O
A
T
P
1
B
3
B
C
R
P
[1
9
]
N
S
5
A
in
h
ib
it
o
rs
D
ac
la
ta
sv
ir
C
Y
P
3
A
4
P
-g
p
P
-g
p
O
A
T
P
1
B
1
O
C
T
1
B
C
R
P
[2
3
]
L
ed
ip
as
v
ir
M
et
ab
o
li
sm
u
n
k
n
o
w
n
,
u
n
ch
an
g
ed
le
d
ip
as
v
ir
is
th
e
m
aj
o
r
co
m
p
o
u
n
d
in
fe
ce
s
P
-g
p
B
C
R
P
P
-g
p
B
C
R
P
[2
9
]
E
lb
as
v
ir
C
Y
P
3
A
4
B
C
R
P
[1
9
]
O
m
b
it
as
v
ir
H
y
d
ro
ly
si
s
fo
ll
o
w
ed
b
y
o
x
id
at
iv
e
m
et
ab
o
li
sm
U
G
T
1
A
1
[2
0
]
N
S
5
B
p
o
ly
m
er
as
e
in
h
ib
it
o
rs
S
o
fo
sb
u
v
ir
/G
S
-3
3
1
0
0
7
H
ep
at
ic
n
o
n
-e
n
zy
m
at
ic
m
et
ab
o
li
sm
E
li
m
in
at
io
n
re
n
al
ly
S
o
fo
sb
u
v
ir
:
P
-g
p
S
o
fo
sb
u
v
ir
:
B
C
R
P
G
S
-3
3
1
0
0
7
is
n
o
t
a
su
b
st
ra
te
o
f
P
-g
p
o
r
B
C
R
P
S
o
fo
sb
u
v
ir
is
a
n
u
cl
eo
si
d
e
an
al
o
g
u
e
tr
ip
h
o
sp
h
at
e.
S
o
fo
sb
u
v
ir
(p
ro
d
ru
g
)
is
m
et
ab
o
li
ze
d
in
G
S
-4
6
1
2
0
3
an
d
G
S
-3
3
1
0
0
7
[2
6
]
1474 E. J. Smolders et al.
interactions with P-gp inhibitors take place at the BBB.
This is affected by the systemic concentration of the P-gp
substrate instead of the concentration in the lumen.
Therefore, it is difficult to predict possible interactions
between DAAs and psychoactive drugs from these results.
Additionally, the clinical relevance of P-gp inhibition by
DAAs depends on the inhibitory potential of the perpe-
trator and the therapeutic range of the victim (see Sect. 4).
Many DAAs are inhibitors of organic anion-transporting
polypeptide (OATP) 1B1 and OATP1B3, which are uptake
transporters. No psychoactive drug is a substrate of
OATPs; hence, these transporters are not discussed in this
review.
3.4 Drug Transporters: DAAs as Victims
Most DAAs are substrates of P-gp and OATPs; therefore,
DAAs are possible victims when psychoactive agents
inhibit or induce these transporters. However, there are
limited data available on psychoactive agents and trans-
porters. An example demonstrating the importance of a
transporter-mediated interaction is the contraindication of
the co-administration of grazoprevir with OATP1B1/3
inhibitors.
4 DDI Mechanisms: Psychoactive Agents
Table 2 provides an overview of the enzymes and trans-
porters involved in the metabolism of psychoactive agents.
In this section, we describe the mechanisms by which
psychoactive agents can be victims and perpetrators of
DDIs.
4.1 Psychoactive Agents as Perpetrators
In general, psychoactive agents are more often victims of
DDIs than perpetrators. For example, benzodiazepines
have limited influence on drug-metabolizing enzymes and
transporters (Table 2).
Various antipsychotics, SSRIs, and TCAs have the
potential to inhibit CYP2D6, which makes these drugs
perpetrators of drug interactions. However, the currently
available DAAs are not metabolized by CYP2D6 and
therefore DDIs via this pathway are not expected
(Tables 2, 3).
4.2 Psychoactive Agents as Victims
Most benzodiazepines are substrates of various CYP
enzymes, such as CYP3A4, CYP2B6, CYP2C19, and
CYP1A2; therefore, benzodiazepines are potential victims
of DDIs. Benzodiazepines have a narrow therapeutic rangeT
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Table 2 Overview of the route of metabolism, effects on enzymes, and transporters of psychoactive agents
Drug Enzyme Transporter References
Substrate Inhibitor Substrate Inhibitor
Benzodiazepines
Alprazolam CYP3A4 (major) CYP3A4 (weak) [38]
Bromazepam CYP1A2 (major)
CYP3A4 (minor)
CYP2E1 (weak)
Brotizolam CYP3A4
Chlordiazepoxide CYP3A4 (major) [39]
Clobazam CYP2C19 (major)
CYP2B6 (minor)
CYP3A4 (minor)
CYP2D6 (moderate)
CYP2C19 (weak)
Inducer: CYP3A4 (weak)
P-gp [40]
Clorazepate CYP3A4 (major) [41]
Diazepam CYP3A4 (major)
CYP2C19 (major)
CYP1A2 (minor)
CYP2B6 (minor)
CYP2C9 (minor)
CYP2C19 (weak)
CYP3A4
[42]
Flurazepam CYP3A4 (major) CYP2E1 (weak) [43]
Lorazepam Conjugation (UGT)
Lormetazepam Conjugation (UGT)
Midazolam CYP3A4 (major)
CYP2B6 (minor)
CYP2C8 (weak)
CYP2C9 (weak)
CYP3A4 (weak)
[44]
Oxazepam UGT
Temazepam UGT (major)
CYP2B6 (minor)
CYP2C19 (minor)
CYP3A4 (minor)
CYP2C9 (minor)
[45]
Zolpidem CYP3A4 (major)
CYP1A2 (minor)
CYP2C19 (minor)
CYP2D6 (minor)
[46]
Zopiclone CYP3A4 (major)
CYP2C8 (minor)
Selective serotonin reuptake inhibitors (SSRIs)
Citalopram CYP3A4 (major)
CYP2C19 (major)
CYP2D6 (minor)
CYP2D6 (weak)
CYP2C19 (weak)
CYP1A2 (weak)
CYP2B6 (weak)
[47]
Duloxetine CYP1A2 (major)
CYP2D6 (major)
CYP2D6 (moderate) [48]
Escitalopram CYP3A4 (major)
CYP2C19 (major)
CYP2D6 (weak) [49]
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Table 2 continued
Drug Enzyme Transporter References
Substrate Inhibitor Substrate Inhibitor
Fluoxetine CYP2C9 (major)
CYP2D6 (major)
CYP1A2 (minor)
CYP2B6 (minor)
CYP2C19 (minor)
CYP2E1 (minor)
CYP3A4 (minor)
CYP2D6 (strong)
CYP2C19 (moderate)
CYP1A2 (weak)
CYP2B6 (weak)
CYP2C9 (weak)
[50]
Fluvoxamine CYP2D6 (major)
CYP1A2 (major)
CYP2C19 (strong)
CYP1A2 (strong)
CYP2B6 (weak)
CYP2C9 (weak)
CYP2D6 (weak)
CYP3A4 (weak)
[51]
Paroxetine CYP2D6 (major) CYP2D6 (strong)
CYP2B6 (moderate)
CYP2C19 (weak)
CYP2C9 (weak)
CYP1A2 (weak)
[52]
Sertraline CYP2C19 (minor)
CYP3A4 (minor)
CYP2B6 (minor)
CYP2D6 (minor)
CYP2C9 (minor)
CYP2B6 (moderate)
CYP2C19 (moderate)
CYP2D6 (moderate)
CYP1A2 (weak)
CYP2C8 (weak)
CYP2C9 (weak)
[53]
Trazodone CYP3A4 (major)
CPY2D6 (minor)
Inducer: P-gp
Venlafaxine CYP2D6 (major)
CYP3A4 (major)
CYP2C9 (minor)
CYP2C19 (minor)
CYP2B6 (weak)
CYP2D6 (weak)
CYP3A4 (weak)
[54]
Vortioxetine CYP2D6 (major)
CYP3A4/5 (major)
CYP2C9 (minor)
CYP2C19 (minor)
CYP2C8 (minor)
CYP2B6 (minor)
CYP2A6 (minor)
P-gp (minor) P-gp (weak) [55]
Tricylic antidepressants (TCAs)
Amitriptyline CYP2D6 (major)
CYP1A2 (minor)
CYP2B6 (minor)
CYP2C19 (minor)
CYP2C9 (minor)
CYP3A4 (minor)
CYP1A2 (weak)
CYP2C19 (weak)
CYP2C9 (weak)
CYP2D6 (weak)
CYP2E1 (weak)
P-gp
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Table 2 continued
Drug Enzyme Transporter References
Substrate Inhibitor Substrate Inhibitor
Clomipramine CYP1A2 (major)
CYP2C19 (major)
CYP2D6 (major)
CYP3A4 (minor)
CYP2D6 (moderate) [56]
Dosulepin COMT
Doxepin CYP2D6 (major)
CYP1A2 (minor)
CYP2C19 (minor)
CYP3A4 (minor)
Imipramine CYP2C19 (major)
CYP2D6 (major)
CYP1A2 (minor)
CYP2B6 (minor)
CYP3A4 (minor)
CYP2D6 (moderate)
CYP1A2 (weak)
CYP2C19 (weak)
CYP2E1 (weak)
Maprotiline CYP2D6 (major)
Nortriptyline CYP2D6 (major)
CYP1A2 (minor)
CYP2C19 (minor)
CYP3A4 (minor)
CYP2D6 (weak)
CYP2E1 (weak)
P-gp
Other antidepressants
Agomelatine CYP1A2
CYP2C9
CYP2C19
Bupropion CYP2B6 (major)
CYP1A2 (minor)
CYP2A6 (minor)
CYP2C9 (minor)
CYP2D6 (minor)
CYP2E1 (minor)
CYP3A4 (minor)
CYP2D6 (strong) OCT2
Mianserin CYP2D6
Mirtazapine CYP1A2 (major)
CYP2D6 (major)
CYP3A4 (major)
CYP2C9 (minor)
CYP1A2 (weak)
Moclobemide CYP2C19 (major)
CYP2D6 (minor)
CYP2C19 (moderate)
CYP1A2 (weak)
CYP2D6 (weak)
(MAO)
St John’s wort Inducer: CYP3A4
Inducer: CYP1A2 (possible various CYP enzymes)
Antipsychotics
Aripiprazole CYP2D6 (major)
CYP3A4 (major)
[57]
Bromperidol CYP3A4
CYP2D6
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Table 2 continued
Drug Enzyme Transporter References
Substrate Inhibitor Substrate Inhibitor
Clozapine CYP1A2 (major)
CYP2A6 (minor)
CYP2C19 (minor)
CYP2C9 (minor)
CYP2D6 (minor)
CYP3A4 (minor)
CYP2D6 (moderate)
CYP1A2 (weak)
CYP2C19 (weak)
CYP2C9 (weak)
CYP2E1 (weak)
CYP3A4 (weak)
Flupentixol CYP2D6
Fluphenazine CYP2D6 (major)
CYP1A2
CYP1A2 (weak)
CYP2C9 (weak)
CYP2D6 (weak)
CYP2E1 (weak)
Haloperidol CYP2D6 (major)
CYP3A4 (major)
CYP1A2 (minor)
CYP2D6 (moderate)
Lurasidone CYP3A4 (major) CYP3A4 (weak) P-gp [58]
Olanzapine CYP1A2 (major)
CYP2D6 (minor)
UGT
CYP1A2 (weak)
CYP2C19 (weak)
CYP2C9 (weak)
CYP2D6 (weak)
CYP3A4 (weak)
[59]
Paliperidone P-gp (weak) [60]
Perphenazine CYP2D6 (major)
CYP1A2 (minor)
CYP2C19 (minor)
CYP2C9 (minor)
CYP3A4 (minor)
CYP1A2 (weak)
CYP2D6 (weak)
Pimozide CYP3A4 (major)
CYP1A2 (major)
CYP2D6 (major)
CYP2C19 (weak)
CYP2D6 (weak)
CYP2E1 (weak)
Quetiapine CYP3A4 (major)
CYP2D6 (minor)
Risperidone CYP2D6 (major)
CYP3A4 (minor)
CYP2D6 (weak) P-gp
Sertindole CYP2D6
CYP3A4
Zuclopenthixol CYP2D6 (major)
CYP3A4 (minor)
Note that most of these drugs have older registration files and, therefore, possible involvement of transporters and CYP enzymes may not be
studied in sufficient detail per the current standards
Information in this table was compiled from the following sources: European Medicines Association summary of product characteristics, US
Food and Drug Administration prescribing information, and data from Lexicomp, available through http://www.uptodate.com (October 2015)
Note: assignment of major/minor substrate status based on their clinically relevant drug interaction potential (http://www.uptodate.com)
No information about hepatic metabolism and/or drug tranporters were available for: Flunitrazepam, loprazolam, nitrazepam,prazepam, lithium
salts, chlorprothixene, fluspirilene, penfluridol, pericyazine, pipamperone, sulpiride, and tiapride
COMT catechol-O-methyl transferase, CYP cytochrome P450, MAO monoamine oxidase, P-gp P-glycoprotein, UGT uridine diphosphate
glucuronosyltransferase
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and a strong concentration–effect relationship [24]; thus,
increased plasma concentrations are likely to cause
increased toxicity.
Midazolam is a model substrate of CYP3A4; therefore,
interactions between midazolam and DAAs have been
extensively studied. For example, oral co-administration of
midazolam and boceprevir resulted in an increase in the
midazolam AUC of 430 % and an increase in its Cmax of
177 %. As a result, co-administration of midazolam and
boceprevir is contraindicated [17]. Similarly, an increase in
the plasma concentration of midazolam is expected when it
is administered with paritaprevir/ritonavir, ombitasvir, and
dasabuvir; therefore, this co-administration is also con-
traindicated [20]. Interactions between midazolam and
simeprevir or grazoprevir have both been studied and
increased midazolam AUC and Cmax values were observed;
thus, caution is needed with co-administration [18, 19]. On
the other hand, daclatasvir has been shown to have little
effect on midazolam exposure [23].
SSRIs are hepatically metabolized by various CYP
enzymes (e.g., CYP3A4, CYP2D6, CYP2C9, and
CYP2C19), particularly CYP3A4. Theoretically, this puts
patients at risk when they are also taking DAAs. However,
SSRIs have a broad therapeutic range; therefore, increased
plasma concentrations of SSRIs are not likely to result in
significant toxicities [10]. For instance, the co-administra-
tion of escitalopram (CYP3A4 substrate) and DAAs such
as boceprevir, simeprevir, or the combination of pari-
taprevir/ritonavir, ombitasvir, and dasabuvir did not result
in a clinically relevant increase in the escitalopram plasma
concentration [17, 18, 20].
Antipsychotics are metabolized in the liver by a variety
of CYP enzymes, as shown in Table 2. CYP3A4 and
CYP2D6 are involved in this metabolism; however, they
can be inhibited by DAAs. Most antipsychotics have a
narrow therapeutic range. Therefore, DDIs involving
antipsychotics can result in clinically relevant outcomes,
especially with strong CYP3A4 inhibitors such as
boceprevir and ritonavir. However, no interaction studies
have been conducted so far. Theoretically, interactions
might occur with, for example, strong CYP3A4 inhibitors
such as boceprevir and ritonavir.
5 Clinical Guidance
In this section, we provide guidance for clinical decision
making regarding the use of a combined treatment of DAAs
and psychoactive drugs.Most potential drug interactions have
not been subjected to rigid pharmacokinetic testing inhumans,
and recommendations are often based on theoretical inter-
pretations of the pharmacokinetics characteristics of drugs.
We believe that a relevant interaction only occurs when
a drug (victim) is metabolized to a ‘major’ or ‘moderate’
extent. Major or moderate substrate status is based on the
potential clinically relevant drug interaction as described
by Lexicomp [15]. A major status indicates that the regi-
men should be modified, whereas a moderate status implies
that the therapy should be monitored. Consequently, a drug
should have strong ([5-fold increase in substrate AUC) or
moderate (2- to 5-fold increase in substrate AUC) influence
on an enzyme/transporter (perpetrator) in order to cause an
interaction (Tables 4, 5, 6, 7, 8, 9, 10).
5.1 Protease Inhibitors
5.1.1 Boceprevir
Table 4 shows benzodiazepines, antidepressants, and
antipsychotics that are safe to combine with boceprevir. Of
the currently available DAAs, boceprevir is one of the most
potent CYP3A4 inhibitors. Therefore, we do not recom-
mend combining boceprevir and drugs primarily metabo-
lized by CYP3A4, especially if they have a narrow
therapeutic range (a contraindication).
Co-administration of midazolam and boceprevir (both
oral and parenteral) is contraindicated since the midazolam
AUC and Cmax are both significantly increased [17]. This
exceptional increase was not observed with other DAAs,
which emphasizes the strong inhibitory potential of
boceprevir on CYP3A4.
On the other hand, no dose adjustment is required when
escitalopram is administered with boceprevir. This is
unexpected as escitalopram is a CYP3A4 substrate. It is
possible that there is involvement of other unknown
enzymes or transporters; hence, the underlying mechanism
cannot be explained [17].
Boceprevir is also a P-gp inhibitor. Theoretically, this
inhibition could have an impact on P-gp substrates;
however, it seems to have minimal clinical relevance due
to the mild inhibition of P-gp by boceprevir [17, 22].
Boceprevir may not be a victim of any DDIs with ben-
zodiazepines, SSRIs, TCAs, or antipsychotics, as studies
with midazolam and escitalopram have shown [17].
Additionally, interaction studies between St John’s wort
and boceprevir showed no alterations in the plasma con-
centration of boceprevir; hence, this combination is safe
to use [17, 21].
Finally, physicians should take care when prescribing
boceprevir in combination with drugs that might prolong
the QT interval and are metabolized by CYP3A4 [17]. For
instance, SSRIs and TCAs may influence the QT interval
and serious pharmacodynamic interactions may occur
when they are administered with boceprevir (Table 4).
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Table 4 Overview of safe options for and contraindicated psychoactive agents that have a potential interaction with boceprevir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepines Bromazepam
Clobazam
Flunitrazepam
Lorazepam
Lormetazepam
Nitrazepam
Oxazepam
Prazepam
Temazepam
Midazolam (oral and intravenous) Alprazolam
Brotizolam
Chlordiazepoxide
Clorazepate
Diazepam
Flurazepam
Zolpidem
Zopiclone
Loprazolam
Antidepressants SSRIs
Citaloprama
Duloxetine
Escitaloprama
Fluoxetineb
Fluvoxamine
Paroxetineb
Sertralineb
TCAs
Amitriptylineb
Clomipraminec
Dosulepin
Doxepinb
Imipraminec
Maprotiline
Nortriptylinec
Others
Agomelatine
Bupropion
Lithium saltsc
Mianserin
Mirtazapinec
Moclobemide
St John’s wort
N/A SSRIs
Trazodone
Venlafaxine
Vortioxetine
TCAs
N/A
Others
N/A
N/A
Antipsychotics Clozapinec
Flupentixol
Fluphenazine
Fluspirilene
Olanzapinec
Paliperidonec
Perphenazine
Sulpridea
Tiapride
Zuclopenthixol
Pimozidea
Quetiapine
Aripiprazolec
Bromperidol
Haloperidola
Lurasidone
Risperidonec
Sertindolec
Chlorprothixene
Penfluridol
Pericyazine
Pipamperone
N/A not applicable, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic antidepressants
a Known risk for prolongation of the QT interval (http://www.crediblemeds.org)
b Conditional risk for prolongation of the QT interval (http://www.crediblemeds.org)
c Possible risk for prolongation of the QT interval (http://www.crediblemeds.org)
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5.1.2 Simeprevir
Table 4 shows psychoactive medications that can be safely
combined with simeprevir. Simeprevir inhibits intestinal
CYP3A4 and therefore only interactions with orally
administered medications are relevant. Thus, intravenous
midazolam can be used safely with simeprevir but oral
midazolam should be used with caution, as the AUC and
Cmax of midazolam are increased by 45 and 31 %,
respectively, when the two are co-administered [18].
Studies have been conducted of escitalopram and it can
be safely used in combination with simeprevir [18].
Simeprevir inhibits P-gp and OATP1B1. Simeprevir has
a higher impact than boceprevir on the transport activity of
Table 5 Overview of safe
options for and contraindicated
psychoactive agents that have a
potential interaction with
simeprevir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepine Bromazepam
Flunitrazepam
Lorazepam
Lormetazepam
Midazolam iv
Nitrazepam
Oxazepam
Prazepam
Temazepam
N/A Alprazolam
Brotizolam
Chlordiazepoxide
Clobazam
Clorazepate acid
Diazepam
Flurazepam
Midazolam po
Zolpidem
Zopiclone
Loprazolam
Antidepressants SSRIs
Citalopram
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
TCAs
Clomipramine
Dosulepin
Doxepin
Imipramine
Maprotiline
Others
Agomelatine
Bupropion
Lithium salts
Mianserin
Moclobemide
N/A SSRIs
Trazodone
Venlafaxine
Vortioxetine
TCAs
Amitriptyline
Nortriptyline
Others
Mirtazapine
St John’s wort
N/A
Antipsychotics Clozapine
Flupentixol
Fluspirilene
Fluphenazine
Olanzapine
Perphenazine
Sulpride
Tiapride
Zuclopenthixol
N/A Aripiprazole
Bromperidol
Haloperidol
Lurasidone
Paliperidone
Pimozide
Quetiapine
Risperidone
Sertindole
Chlorprothixene
Penfluridol
Pericyazine
Pipamperone
iv intravenous, N/A not applicable, po oral, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic
antidepressants
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Table 6 Overview of safe options for and contraindicated psychoactive agents that have a potential interaction with daclatasvir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepine Alprazolam
Bromazepam
Brotizolam
Chlordiazepoxide
Clorazepate
Diazepam
Flunitrazepam
Flurazepam
Lorazepam
Lormetazepam
Midazolam
Oxazepam
Nitrazepam
Prazepam
Temazepam
Zolpidem
Zopiclone
N/A Clobazam Loprazolam
Antidepressants SSRIs
Citalopram
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Trazodone
Venlafaxine
Vortioxetine
TCAs
Clomipramide
Dosulepin
Doxepin
Imipramine
Maprotiline
Others
Agomelatine
Bupropion
Lithium salts
Mianserin
Mirtazapine
Moclobemide
St John’s wort SSRIs
N/A
TCAs
Amitriptyline
Nortriptyline
Others
N/A
N/A
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P-gp, as indicated in Sect. 3.3. Therefore, inhibition of P-gp
by simeprevir may lead to a small increase in concentra-
tions of P-gp substrates (e.g., risperidone and nortriptyline)
in the brain. However, the clinical relevance seems limited
[18].
Simeprevir is a possible victim of DDIs as it is primarily
metabolized by CYP3A4 [18]. St John’s wort may there-
fore cause a decrease in the plasma concentration of
simeprevir as it is a CYP3A4 inducer. Nevertheless, this
change might not be clinically relevance since simeprevir
exhibits high inter-individual variability in its plasma
concentrations [25].
5.2 NS5A Inhibitor
5.2.1 Daclatasvir
Daclatasvir has a negligible influence on the activities of
CYP3A4 and other CYP enzymes and no dose adjustments
were required when it was studied with midazolam [23].
Based on this information, it is expected that most ben-
zodiazepines, antidepressants, and antipsychotics can be
used safely in combination with daclatasvir, as shown in
Table 6. Daclatasvir is metabolized by CYP3A4 and thus
inducers and inhibitors of CYP3A4 have the ability to
affect the plasma concentrations of daclatasvir [23]. Most
psychoactive drugs do not influence CYP3A4, with the
exception of St John’s wort; therefore, co-administration of
St John’s wort and daclatasvir is contraindicated [23].
5.3 NS5B Polymerase Inhibitor
5.3.1 Sofosbuvir
Sofosbuvir is an NS5B inhibitor and not a perpetrator of
DDIs as it has no influence on CYP enzymes or drug
transporters; therefore, it has no impact on the plasma
concentrations of psychoactive drugs [26]. However, an
unexpected interaction has occurred involving sofosbuvir
and the antiarrhythmic agent amiodarone. This indicates
that not every DDI can be predicted based on the activities
of CYP, UGT, or drug transporters. The mechanism and
the specific role of sofosbuvir in the interaction was
uncertain because other DAAs (daclatasvir, simeprevir, and
ledipasvir) were simultaneously administered and could
have been involved in causing the interaction [27, 28].
Additionally, it could also be caused by a pharmacody-
namic interaction.
Sofosbuvir is metabolized in the liver and intestine; the
drug is not a victim of enzymatic DDIs because it is not
metabolized by, for example, CYPs or UGTs [26]. Sofos-
buvir is a substrate for P-gp and BCRP; hence, interactions
may occur with inducers and inhibitors of P-gp. P-gp
inducers, e.g., St John’s wort, could potentially decrease
Table 6 continued
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Antipsychotics Aripiprazole
Bromperidol
Clozapine
Flupentixol
Fluphenazine
Fluspirilene
Haloperidol
Olanzapine
Perphenazine
Pimozide
Quetiapine
Sertindole
Sulpride
Tiapride
Zuclopenthixol
N/A Lurasidone
Paliperidone
Risperidone
Chlorprothixene
Penfluridol
Pericyazine
Pipamperone
N/A not applicable, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic antidepressants
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Table 7 Overview of safe options for and contraindicated psychoactive agents that have a potential interaction with ledipasvir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepine Alprazolam
Bromazepam
Brotizolam
Chlordiazepoxide
Clorazepate
Diazepam
Flunitrazepam
Flurazepam
Lorazepam
Lormetazepam
Midazolam
Prazepam
Nitrazepam
Oxazepam
Temazepam
Zolpidem
Zopiclone
N/A Clobazam Loprazolam
Antidepressants SSRIs
Citalopram
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Trazodone
Venlafaxine
Vortioxetine
TCAs
Clomipramine
Dosulepin
Doxepin
Imipramine
Maprotiline
Others
Agomelatine
Bupropion
Lithium salts
Mianserin
Mirtazapine
Moclobemide
St John’s wort SSRIs
N/A
TCAs
Amitriptyline
Nortriptyline
Others
N/A
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plasma concentrations of sofosbuvir and result in a
decrease in the pharmacological effects of sofosbuvir.
Therefore, co-administration of the two drugs is con-
traindicated. Trazodone is also a possible P-gp inducer and
may affect the plasma concentration of sofosbuvir
(Table 8). Inhibition of P-gp could increase the plasma
concentration of sofosbuvir; however, the interaction
studies have not been performed in humans [26]. Lastly,
the main (inactive) metabolite of sofosbuvir (GS-331007)
is not a P-gp substrate [26].
5.4 Fixed-Dose Combinations
5.4.1 Ledipasvir and Sofosbuvir
Ledipasvir inhibits P-gp and BCRP and may cause inter-
actions with P-gp and BCRP substrates (e.g., risperidone,
and nortriptyline) [29]. P-gp inhibition at the BBB could
potentially increase the exposure of these P-gp substrates in
the brain. No interaction studies have been performed
between ledipasvir and psychoactive agents. Table 7 shows
the psychoactive agents that can be safely used with or
potentially interact with ledipasvir.
The metabolism of ledipasvir is unknown but it is
mainly excreted unchanged through bile. Thus, ledipasvir
is not expected to be a victim of DDIs [29].
Sofosbuvir is discussed in Sect. 5.3.1.
5.4.2 Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir
Ritonavir is a strong CYP3A4 inhibitor but it also influ-
ences other CYP enzymes and drug transporters.
Consequently, caution is needed if combining drugs
metabolized by CYP3A4 with this fixed-dose regimen
(paritaprevir/ritonavir, ombitasvir, and dasabuvir). Psy-
choactive agents such as duloxetine, escitalopram, zolpi-
dem, alprazolam, and diazepam can be safely administered
with this regimen as previous studies have not shown any
clinically relevant interactions (Table 9) [20, 30–32].
The plasma concentrations of duloxetine did not alter
when it was co-administered with the combination regimen
[20]. Duloxetine is a substrate for CYP2D6 and CYP1A2,
and ritonavir inhibits CYP2D6 and induces CYP1A2. As
no effect was observed when combined with paritaprevir/
ritonavir, ombitasvir, and dasabuvir, it was suggested that
the inhibition of CYP2D6 and induction of CYP1A2
occurred to similar extents. We recommend that this
combination regimen be used with care in patients
receiving medications that are metabolized by CYP2D6
and/or CYP1A2, especially as a previous interaction study
on the co-administration of olanzapine (CYP1A2 and
CYP2D6 substrate) and ritonavir resulted in decreased
olanzapine concentrations [33].
It is important to note that CYP2D6 inhibition by
ritonavir is dose dependent [34]. Low-dose ritonavir
(100 mg twice daily) had only a mild effect on CYP2D6, as
shown with the CYP2D6 substrate desipramine (26 %
AUC increase), but the therapeutic dose of ritonavir
(600 mg twice daily) had a stronger effect (desipramine
AUC increase of 145 %) [34–36]. However, this fixed-dose
HCV regimen contains only 100 mg of ritonavir. There-
fore, we expect DDIs only with co-administered drugs that
are primarily metabolized by CYP2D6 and that have a
narrow therapeutic range. Such drugs are not
Table 7 continued
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Antipsychotics Aripiprazole
Bromperidol
Clozapine
Flupentixol
Fluphenazine
Fluspirilene
Haloperidol
Olanzapine
Perphenazine
Pimozide
Quetiapine
Sertindole
Sulpride
Tiapride
Zuclopenthixol
N/A Lurasidone
Paliperidone
Risperidone
Chlorprothixene
Penfluridol
Pericyazine
Pipamperone
N/A not applicable, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic antidepressants
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Table 8 Overview of safe options for and contraindicated psychoactive agents that have a potential interaction with sofosbuvir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepine Alprazolam
Bromazepam
Brotizolam
Chlordiazepoxide
Clobazam
Clorazepate
Diazepam
Flunitrazepam
Flurazepam
Loprazolam
Lorazepam
Lormetazepam
Midazolam
Oxazepam
Prazepam
Temazepam
Zolpidem
Zopiclone
N/A N/A Loprazolam
Nitrazepam
Antidepressants SSRIs
Citalopram
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Venlafaxine
Vortioxetine
TCAs
Amitriptyline
Clomipramine
Dosulepin
Doxepin
Imipramine
Maprotiline
Nortriptyline
Others
Agomelatine
Bupropion
Lithium salts
Mianserin
Mirtazapine
Moclobemide
St John’s wort SSRIs
Trazodone
TCAs
N/A
Others
N/A
N/A
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contraindicated with this combination regimen; however,
plasma drug concentrations and adverse events should be
monitored after co-administration [34].
Ritonavir also inhibits P-gp; therefore, ritonavir may
modify plasma concentrations of P-gp substrates such as
risperidone and amitriptyline.
Paritaprevir, ombitasvir, and dasabuvir are inhibitors of
UGT and thus benzodiazepines (e.g., lorazepam, lormeta-
zepam, and oxazepam) conjugated by UGT could be vic-
tims of interactions (Table 6) [20].
5.4.3 Grazoprevir and Elbasvir
Table 10 shows safe options for psychoactive drugs that
can be administered with grazoprevir and elbasvir. Gra-
zoprevir is a mild CYP3A inhibitor as it was observed to
increase the plasma concentration of midazolam by only
30 % [19]. Therefore, CYP3A4 substrates are not con-
traindicated for co-administration with grazoprevir. How-
ever, we recommend that prescribers be aware of possible
interactions with drugs that are primarily metabolized by
CYP3A4 and have a narrow therapeutic range. There are
no reported studies on drug interactions between the gra-
zoprevir/elbasvir combination and psychoactive agents
[19]. Grazoprevir and elbasvir are mainly metabolized by
CYP3A4; thus, they should not be administered with St
John’s wort and other CYP3A4 inducers or inhibitors [19]
(Table 10).
6 Conclusion
In this review we have shown that there is a paucity of
experimental data on drug interactions between psychoac-
tive agents and DAAs. Many mechanisms are involved in
the metabolism and transport of both classes of drugs,
making it difficult to predict which drugs can be safely co-
administered to patients.
In our opinion, safe options for concomitant adminis-
tration should be combinations that have actually been
studied in humans, or combinations that are not based on
theoretical pharmacokinetic interactions. In addition, all
medications used at the start of and during HCV treatment
should be inventoried, so that possible DDIs can be evalu-
ated before clinically relevant effects arise. Physicians
should also be aware of possible interactions and their
consequences. These may include adverse effects caused by
increased plasma drug concentrations or reduced efficacy
due to decreases in drug exposure. These are of great
importance as such issues may also affect adherence to both
Table 8 continued
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Antipsychotics Aripiprazole
Bromperidol
Clozapine
Flupentixol
Fluphenazine
Fluspirilene
Haloperidol
Olanzapine
Paliperidone
Perphenazine
Pimozide
Quetiapine
Risperidone
Sertindole
Sulpride
Tiapride
Zuclopenthixol
N/A Lurasidone Chlorprothixene
Penfluridol
Pericyazine
Pipamperone
N/A not applicable, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic antidepressants
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DAAs and psychoactive agents. Our final recommendation
is that physicians contact pharmacists or clinical pharma-
cologists for support in managing these interactions.
This review provides an overview of the mechanisms of
interactions between DAAs and psychoactive agents.
Based on interaction studies, we give recommendations for
Table 9 Overview of safe
options for and contraindicated
psychoactive agents that have a
potential interaction with
paritaprevir, ritonavir,
ombitasvir plus dasabuvir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepine Alprazolam
Bromazepam
Clobazam
Diazepam
Flunitrazepam
Prazepam
Nitrazepam
Zolpidem
Midazolam Brotizolam
Clorazepate
Chlordiazepoxide
Flurazepam
Lorazepam
Lormetazepam
Oxazepam
Temazepam
Zopiclone
Loprazolam
Antidepressants SSRIs
Citalopram
Escitalopram
Duloxetinea
TCAs
Dosulepin
Others
Lithium salts
Moclobemide
St John’s wort SSRIs
Fluoxetinea
Fluvoxaminea
Paroxetinea
Sertraline
Trazodone
Venlafaxinea
Vortioxetinea
TCAs
Amitriptylinea
Clomipramine
Doxepina
Imipraminea
Nortriptylinea
Maprotilinea
Others
Agomelatine
Bupropion
Mirtazepine
Mianserina
N/A
Antipsychotics Fluspirilene
Sulpride
Tiapride
Pimozide
Quetiapine
Aripiprazolea
Bromperidola
Clozapine
Flupentixola
Fluphenazinea
Haloperidola
Lurasidone
Olanzapine
Paliperidone
Perphenazinea
Risperidonea
Sertindolea
Zuclopenthixol
Chlorprothixene
Penfluridol
Pericyazine
Pipamperone
N/A not applicable, SSRIs selective serotonin reuptake inhibitors, TCAs tricyclic antidepressants
a Substrates of CYP2D6 (Sect. 5.4.1)
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Table 10 Overview of safe options for and contraindicated psychoactive agents that have a potential interaction with grazoprevir plus elbasvir
Class of psychoactive agent Safe options Contraindicated Potential interaction Unknown
Benzodiazepine Alprazolam
Brotizolam
Chlordiazepoxide
Bromazepam
Clobazam
Flunitrazepam
Lorazepam
Lormetazepam
Clorazepate
Flurazepam
Nitrazepam
Oxazepam
Temazepam
Prazepam
Zolpidem
Zopiclone
N/A Diazepam
Midazolam
Loprazolam
Antidepressants SSRIs
Citalopram
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Trazodone
Venlafaxine
Vortioxetine
TCAs
Amitriptyline
Clomipramine
Dosulepin
Doxepin
Imipramine
Maprotiline
Nortriptyline
Others
Agomelatine
Bupropion
Lithium salts
Mianserin
Mirtazapine
Moclobemide
St John’s wort SSRIs
N/A
TCAs
N/A
Others
N/A
N/A
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the co-administration of DAAs and psychoactive agents.
The administration of various combinations of drugs results
in different potential interactions. It is therefore necessary
that theoretical predictions of DDIs be backed with actual
drug interaction studies, in order to obtain more conclusive
and useful data for clinical applications.
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